ArticleThe New England journal of medicine2015
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- The relationship between genetic mutations and organ metastasis in non-small cell lung cancer.Therapeutic advances in medical oncology · 2026Review
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.BMC cancer · 2025Article
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse.Cold Spring Harbor perspectives in medicine · 2024Review
- P40 and TTF-1 double-expressing non-small cell lung cancer with EML4-ALK and PIK3CA gene mutations: A case report and review of the literature.Oncology letters · 2023Article
- Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review.Lung Cancer (Auckland, N.Z.) · 2023Review
- Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.Molecular biomedicine · 2022Review
- Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2022Review
- Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.Molecular cancer therapeutics · 2022Article
- A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.NPJ precision oncology · 2021Article
- Correlating ROS1 Protein Expression WithJTO clinical and research reports · 2021Article
- Prognostic effects of the expression of inhibitor of DNA-binding family members on patients with lung adenocarcinoma.Oncology letters · 2020Article
- Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.Thoracic cancer · 2020Article
- The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.Translational lung cancer research · 2019Review
- Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods.Genome biology · 2019Article
- Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.BMC cancer · 2019Article
- Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.Cancer research · 2019Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25671264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.